Results     25-May-19
Announcements
Astrazeneca Pharma India standalone net profit rises 204.97% in the March 2019 quarter
Sales rise 26.25% to Rs 190.30 crore
Net profit of Astrazeneca Pharma India rose 204.97% to Rs 9.82 crore in the quarter ended March 2019 as against Rs 3.22 crore during the previous quarter ended March 2018. Sales rose 26.25% to Rs 190.30 crore in the quarter ended March 2019 as against Rs 150.73 crore during the previous quarter ended March 2018.

For the full year,net profit rose 110.11% to Rs 54.44 crore in the year ended March 2019 as against Rs 25.91 crore during the previous year ended March 2018. Sales rose 27.55% to Rs 728.29 crore in the year ended March 2019 as against Rs 571.00 crore during the previous year ended March 2018.

ParticularsQuarter EndedYear Ended
 Mar. 2019Mar. 2018% Var.Mar. 2019Mar. 2018% Var.
Sales190.30150.73 26 728.29571.00 28
OPM %3.3510.13 -9.798.11 -
PBDT12.3817.61 -30 87.5858.54 50
PBT8.4714.06 -40 72.6643.80 66
NP9.823.22 205 54.4425.91 110

Previous News
  Astrazeneca Pharma India standalone net profit rises 96.78% in the June 2022 quarter
 ( Results - Announcements 08-Aug-22   14:55 )
  Astrazeneca Pharma gains after CDSCO nod to sale Tremelimumab solution
 ( Hot Pursuit - 02-Jun-23   10:05 )
  Astrazeneca Pharma India Ltd leads losers in 'A' group
 ( Hot Pursuit - 09-Feb-24   15:00 )
  AstraZeneca receives DCGI approval for launch of Olaparib Film-Coated tablets in India
 ( Corporate News - 19-Aug-22   19:06 )
  Astrazeneca Pharma India to declare Quarterly Result
 ( Corporate News - 02-Aug-21   17:55 )
  Castrol India Ltd leads gainers in 'A' group
 ( Hot Pursuit - 22-Dec-23   12:00 )
  Astrazeneca Pharma India to declare Quarterly Result
 ( Corporate News - 20-May-22   14:17 )
  AstraZeneca Pharma receives DCGI approval for launch of Benralizumab (Fasenra™) in India
 ( Corporate News - 21-Dec-20   08:55 )
  Astrazeneca Pharma India to table results
 ( Corporate News - 31-Oct-23   14:03 )
  Astrazeneca Pharma India standalone net profit declines 54.63% in the September 2021 quarter
 ( Results - Announcements 10-Nov-21   08:11 )
  AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
 ( Corporate News - 22-Jun-18   09:58 )
Other Stories
  Kronox Lab Sciences standalone net profit rises 140.98% in the March 2024 quarter
  29-Jun-24   07:31
  Performance Chemiserve standalone net profit rises 6062.22% in the March 2024 quarter
  27-Jun-24   07:24
  Sundew Properties standalone net profit rises 119.15% in the March 2024 quarter
  27-Jun-24   07:24
  IKF Home Finance standalone net profit rises 42.15% in the March 2024 quarter
  27-Jun-24   07:24
  Delhi Transco standalone net profit rises 1.08% in the March 2024 quarter
  27-Jun-24   07:24
  Profectus Capital Pvt standalone net profit rises 12.12% in the March 2024 quarter
  27-Jun-24   07:24
  Shrem Infra Invest Pvt consolidated net profit rises 290.12% in the March 2024 quarter
  27-Jun-24   07:24
  Bharat Ekansh reports consolidated net loss of Rs 0.01 crore in the March 2024 quarter
  27-Jun-24   07:24
  Patel KNR Heavy Infrastructures reports standalone net loss of Rs 2.71 crore in the March 2024 quarter
  27-Jun-24   07:24
  Supreme Infrastructure India reports consolidated net loss of Rs 326.26 crore in the March 2024 quarter
  26-Jun-24   07:29
Back Top